SynthesisBiomolecules & biomedicine2025
The role of COPD in survival of NSCLC patients receiving immune checkpoint inhibitors: A meta-analysis.
Synthesis in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impact of chronic obstructive pulmonary disease (COPD) on the survival of patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs) remains unclear. Given the growing use of ICIs in NSCLC treatment and the high prevalence of COPD among these patients, understanding this relationship is essential. This meta-analysis aims to evaluate the association between COPD and survival outcomes in NSCLC patients treated with ICIs. A systematic search was conducted in PubMed, Embase, and Web of Science from inception to February 10, 2025. Observational studies reporting survival outcomes in NSCLC patients with and without COPD undergoing ICI therapy were included. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using a random-effects model to account for heterogeneity. Thirteen retrospective cohort studies involving 5,564 patients were included. COPD was associated with improved progression-free survival (PFS) (HR: 0.68, 95% CI: 0.54-0.85, p < 0.001) and overall survival (OS) (HR: 0.80, 95% CI: 0.68-0.95, p = 0.01) in NSCLC patients receiving ICIs. Heterogeneity was moderate (I² = 46% for PFS, I² = 43% for OS). Subgroup analyses indicated that the association between COPD and survival outcomes was consistent across study regions (Asian vs. Western countries), patient age, sex distribution, COPD diagnostic criteria (spirometry, clinical diagnosis, or CT-diagnosed emphysema), follow-up duration, analytic models (univariate vs. multivariate), and study quality scores (p for subgroup differences > 0.05). Furthermore, univariate meta-regression analysis showed no significant modification of results by sample size, mean age, sex distribution, follow-up duration, or study quality scores (all p > 0.05).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.